10:50 AM EDT, 05/22/2024 (MT Newswires) -- Zai Lab ( ZLAB ) said Wednesday the first patient has been dosed in a phase 2 clinical trial of its ZL-1102 therapy to treat chronic plaque psoriasis, an inflammatory autoimmune skin disease.

The primary endpoint is the proportion of patients achieving at least a 75% reduction in the modified Psoriasis Area Severity Index

score from baseline, at week 16.

Roughly 250 patients will receive topical therapy for 16 weeks in the five-arm trial, the company said.

Zai Lab ( ZLAB ) shares were up more than 2% in recent trading.

Price: 20.56, Change: +0.55, Percent Change: +2.75